Seroprevalence of Toxoplasma gondii Infection and Characteristics of Seropositive Patients in General Hospitals in Daejeon, Korea

Shin, Dong–Min; Yeub, Dong; Hua, Quan Juan; Cha, Guang-Ho; Lee, Young Ha

doi:10.3347/kjp.2009.47.2.125

Cited by 88 publications

(64 citation statements)

References 16 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The global seroprevalence in humans and animals varies greatly among countries, ranging from 6.7% in Korea to 68.6% in Brazil, depending on the geographical location and differences in lifestyle [2][3]. The authors of a previous systematic review of the Iranian general population estimated that approximately 39.3% (95% CI, 33.0 to 45.7) of individuals were seropositive [4].…”

Section: Introductionmentioning

confidence: 99%

Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis

Ahmadpour

Daryani

Sharif

et al. 2014

J Infect Dev Ctries

119

View full text Add to dashboard Cite

Although toxoplasmosis in immunocompetent individuals is generally asymptomatic, in immunocompromised patients (HIV/AIDS, cancer, and transplant patients), it can lead to serious pathological effects. This study included a systematic review and meta-analysis to comprehensively assess the seroprevalence rate of Toxoplasma infection in immunocompromised patients in Iran. Electronic English and Persian databases (PubMed, Google Scholar, ScienceDirect, Scopus, Magiran, Scientific Information Database [SID], IranMedex, and IranDoc), parasitology congresses, and projects and theses of Iranian medical universities, were systematically searched from 1997 to 2013 (published or unpublished data). In this paper, several studies that used serological methods for diagnosis of toxoplasmosis were selected. Analysis of seroprevalence estimates was pooled using a random-effects meta-analysis. Twenty-two studies, comprising 2,805 individuals, were included in the meta-analysis. Overall seroprevalence rate of Toxoplasma infection in Iranian immunocompromised patients was 50.01% (95% confidence interval, 43.85 to 56.17); however, there was significant heterogeneity among study groups. The results showed that seroprevalence rate of toxoplasmosis among transplant recipients, HIV/AIDS, and cancer patients in Iran was 55.1%, 50.05%, and 45.06%, respectively. In addition, IgM seroprevalence rate was estimated to be 4.85% (95% confidence interval, 2.22 to 8.41). This systematic review and meta-analysis identified a high seroprevalence rate of Toxoplasma infection among immunocompromised patients (50%).Consideration of management , design and provision of appropriate control measures of toxoplasmosis is highly recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis

Ahmadpour

Daryani

Sharif

et al. 2014

J Infect Dev Ctries

119

View full text Add to dashboard Cite

show abstract

“…As such, these ELISAs may be used as a marker for active Toxoplasma infection in IC patients (429). A latex agglutination test (519) and several other ELISAs are also available for the detection of anti-Toxoplasma antibodies (2,338,519,613).…”

Section: Toxoplasma Gondiimentioning

confidence: 99%

Importance of Nonenteric Protozoan Infections in Immunocompromised People

et al. 2010

View full text Add to dashboard Cite

SUMMARY There are many neglected nonenteric protozoa able to cause serious morbidity and mortality in humans, particularly in the developing world. Diseases caused by certain protozoa are often more severe in the presence of HIV. While information regarding neglected tropical diseases caused by trypanosomatids and Plasmodium is abundant, these protozoa are often not a first consideration in Western countries where they are not endemic. As such, diagnostics may not be available in these regions. Due to global travel and immigration, this has become an increasing problem. Inversely, in certain parts of the world (particularly sub-Saharan Africa), the HIV problem is so severe that diseases like microsporidiosis and toxoplasmosis are common. In Western countries, due to the availability of highly active antiretroviral therapy (HAART), these diseases are infrequently encountered. While free-living amoebae are rarely encountered in a clinical setting, when infections do occur, they are often fatal. Rapid diagnosis and treatment are essential to the survival of patients infected with these organisms. This paper reviews information on the diagnosis and treatment of nonenteric protozoal diseases in immunocompromised people, with a focus on patients infected with HIV. The nonenteric microsporidia, some trypanosomatids, Toxoplasma spp., Neospora spp., some free-living amoebae, Plasmodium spp., and Babesia spp. are discussed.

show abstract

“…In Brazil, toxoplasmosis is an important public health problem in many areas, with serological prevalence ranging from 50-84% for T. gondii infection in adults (Bahia-Oliveira et al, 2003;Spalding et al, 2005). Shin et al (2009) reported that the recent seroprevalence of T. gondii ranges from 0.79-12.9% in the Korean population. In Turkey, it was reported to be 36% in Kayseri (Zamani et al, 2007) reported that T. gondii infection has shown considerable prevalence in Iran and seropositivity ranges from 5.7-87%.…”

Section: Introductionmentioning

confidence: 99%

Anti-<i>Toxoplasma gondii</i> Antibodies in Haemodialysis Patients

Solhjoo¹

2010

American Journal of Infectious Diseases

View full text Add to dashboard Cite

Problem statement: In situations of immunodeficiency, Toxoplasma gondii emerges as a life-threatening infection. Toxoplasma gondii is transmitted parenterally, flourish in immunocompromised subjects and, most toxoplasma infections are asymptomatic. Studies have shown that there is a immunodeficiency in renal failure patient such as hemodialysis patients and these patients have a high risk for many infections. There is no evidence about toxoplasmosis in hemodialysis patients in Iran. Approach: In the present study, we aimed to investigate the prevalence of anti-T. gondii antibodies in hemodialysis patients with chronic renal failure. This case-control study was carried out on 44 hemodialysis patients and 44 healthy controls for the prevalence of anti-T. gondii antibodies by ELISA. Anti-IgG, IgM and IgA T. gondii antibodies positivity were found to be 26 (59.10%), 3 (6.80%) and 3 (6.80%) of the 44 hemodialysis patients, respectively and 16 (36.40%) of the 44 control subjects were Anti-IgG T. gondii antibodies positivity and all of control subjects were negative for Anti-IgM and IgA T. gondii antibodies. The difference between them was statistically significant (p = 0.032). In addition, an increase of the seropositivity rate was detected with increasing length of time on hemodialysis treatment, indicating a statistically significant difference between these 2 parameters (p<0.001). Results: These findings confirm a high prevalence of toxoplasma infection in hemodialysis patients and these patients are a risk group for toxoplasma infection. Results showed that 3 hemodialysis patients had an acute and active infection. Conclusion: Moreover, it is recommended that hemodialysis patients who are susceptible to toxoplasma infections should be identified by T. gondii IgG and IgM and/or IgA specific serological tests. Therefore, patients undergoing hemodialysis should be screened for toxoplasma before dialysis to prevent the dissemination of this infection through the hemodialysis procedure.

show abstract

Seroprevalence of Toxoplasma gondii Infection and Characteristics of Seropositive Patients in General Hospitals in Daejeon, Korea

Cited by 88 publications

References 16 publications

Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis

Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis

Importance of Nonenteric Protozoan Infections in Immunocompromised People

Anti-<i>Toxoplasma gondii</i> Antibodies in Haemodialysis Patients

Contact Info

Product

Resources

About